- Case-Based Modules
- Initial Evaluation
- Dermatologic Manifestations
- Oral Manifestations
- OIs: Prophylaxis
- OIs: Treatment
- Antiretroviral Rx
- Antiretroviral Rx: Resistance
- Antiretroviral Rx: Adverse Effects
- Drug-Drug Interactions
- Postexposure Prophylaxis
- Perinatal Transmission
- Special Populations
- Prevention for Positives
- Challenging Unknowns
- Resource-Limited Settings
- Interactive Tutorials
- Routine HIV Screening
- Oraquick Advance Rapid HIV Test
- HIV Integration
- This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.
Drug-Drug Interactions
Question | Discussion | References | CME Credit
Updated July 2, 2011
Case 2: Antiretrovirals and Tuberculosis Therapy
| Authors: | Bradley W. Kosel, PharmD David H. Spach, MD |
- Understand the drug-drug interactions that occur with rifamycins (rifampin and rifabutin) and the non-nucleoside reverse transcriptase inhibitors (NNRTIs).
- Understand the drug-drug interactions that occur with rifamycins (rifampin and rifabutin) and the protease inhibitors (PIs).
A 37-year-old Hispanic male is newly diagnosed with both HIV infection and pulmonary tuberculosis. His laboratory studies show a CD4 count of 6 cells/mm3 and an HIV RNA greater than 500,000 copies/ml. He is started on four-drug therapy for tuberculosis that consists of isoniazid, ethambutol, rifampin, and pyrazinamide. The plan is to start antiretroviral therapy after 2 weeks of anti-tuberculosis therapy. One of two antiretroviral therapy regimens are being considered: (1) tenofovir plus emtricitabine plus efavirenz (Atripla), or (2) tenofovir plus emtricitabine (Truvada) plus darunavir (Prezista) plus ritonavir (Norvir).
Which of the following is TRUE regarding a potential drug-drug interaction?
Copyright © 2004-2013 University of Washington